Xosomix
Xosomix is a biotechnology company focused on developing next-generation therapeutics based on exosomes. They leverage the targeting and healing capabilities of exosomes to improve treatments for brain disorders, addressing a significant unmet medical need in mental health. The company is founded on preclinical research demonstrating the therapeutic use of exosomes in Rett Syndrome and is a resident of JLABS by Johnson & Johnson Innovation.
Industries
Nr. of Employees
small (1-50)
Xosomix
Products
Exosome-based therapeutics for brain disorders
Development-stage therapeutics that use exosomes to deliver biomolecular payloads to brain cells, intended to modify disease course and improve drug efficacy; preclinical work includes application to Rett Syndrome.
Exosome-based therapeutics for brain disorders
Development-stage therapeutics that use exosomes to deliver biomolecular payloads to brain cells, intended to modify disease course and improve drug efficacy; preclinical work includes application to Rett Syndrome.
Services
Preclinical research and development of exosome therapeutics
Research and development activities focused on creating and evaluating exosome-based therapeutics for brain disorders, including preclinical proof-of-concept studies.
Preclinical research and development of exosome therapeutics
Research and development activities focused on creating and evaluating exosome-based therapeutics for brain disorders, including preclinical proof-of-concept studies.
Expertise Areas
- Exosome therapeutics
- Neurological/brain disorder therapeutics
- Preclinical development and translational research
- Targeted drug delivery using extracellular vesicles
Key Technologies
- Exosome / extracellular vesicle engineering
- Targeted biomolecule delivery to specific cells
- Therapeutic payload loading into vesicles
- Preclinical in vivo neurological disease models